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Bisphenol A (BPA) is an industrial chemical 
found in polycarbonate plastics and epoxy 
resins such as food-can linings, bottles, and 
dental fillings. The weak estrogenic activity 
of BPA (Laws et al. 2000; Stoker et al. 1999) 
has raised questions as to its safety in humans. 
Human exposure to BPA is potentially wide-
spread, and young children particularly are 
seen by regulatory authorities as a popula-
tion of special concern [National Toxicology 
Program (NTP) 2008]. Their susceptibility is 
based on their reduced capacity to eliminate 
xenobiotics in general (Hines 2008) as well 
as their estimated higher weight-normalized 
daily exposure to BPA compared with adults 
[European Food Safety Authorities (EFSA) 
2006; NTP 2008]. Having a method to esti-
mate the age dependence of internal BPA 
exposure is critical for developing a reasonable 
assessment of BPA risk to children.
In response to the identification of 
young children as a higher risk population, 
we investigated the exposure of children to 
BPA using physiologically based toxico  kinetic 
(PBTK) modeling. PBTK models have been 
widely used in human health risk assess-
ment to assess the potential internal human 
exposure to environmental compounds in 
the absence of direct human toxicokinetic 
data (Andersen 2003; Bruckner et al. 2004). 
Typically, toxicokinetic data from animals 
are used to build a compound-specific PBTK 
model that is then parameterized with infor-
mation for humans (e.g., blood flows, organ 
volumes) (Bruckner et al. 2004; Young 
et al. 2001). Although interspecies scaling 
represents the primary use of PBTK models, 
intraspecies scaling also represents a valuable 
means for assessing exposures in subpopu-
lations (Edginton et al. 2008). Pharmaco-/
toxicokinetic scaling for the purposes of both 
human health risk assessment and pharma-
ceutical drug development has focused on the 
pediatric subpopulation where physiologically 
based pharmacokinetic models are built for 
adult humans and scaled to children based on 
their physiologic differences (Bjorkman 2005; 
Edginton et al. 2006a, 2006b; Ginsberg et al. 
2004; Yang et al. 2006).
BPA is completely and rapidly absorbed 
from the gastrointestinal tract (Volkel et al. 
2002). Using an ex vivo method, Csanady 
et al. (2002) determined tissue:blood par-
tition coefficients for human tissues after 
incubation with BPA. Because of the high 
lipophilicity of BPA, the adipose:blood parti-
tion coefficient (3.3) was two to three times 
greater than that of the other tested tissues 
(range, 0.9–1.82). Hepatic clearance of BPA 
to its glucuronidated metabolite, BPA-Glu, is 
rapid and complete, and BPA-Glu is the pre-
dominant substance found in plasma (Volkel 
et al. 2002). Urinary excretion is the only 
route of elimination for BPA-Glu (Volkel 
et al. 2002). The toxicokinetics of these sub-
stances have been studied only in adults. 
Toxicokinetic scaling to children using PBTK 
models remains the only means to reasonably 
assess relative internal BPA exposures.
The objectives of this modeling study 
were to estimate the differences in the average 
steady-state dose-normalized BPA plasma and 
urinary concentrations between adults and 
children < 2 years of age after BPA adminis-
tration and to determine the expected average 
steady-state plasma concentrations of BPA 
and BPA-Glu in young children after typical 
feeding scenarios.
Materials and Methods
PBTK Model Structure and Software
In this study we used a nested coupled PBTK 
structure consisting of a BPA submodel cou-
pled to a BPA-Glu submodel (Figure 1). We 
used PK-Sim software (version 4.0; Bayer 
Technology Services GmbH, Leverkusen, 
Germany) to generate each individual sub-
model. Figure 1 graphically presents the 
PBTK model structure implemented in 
PK-Sim [presented by von Kleist and Huisinga 
2007; Willmann et al. 2003a, 2005; described 
by differential and algebraic equations in 
the Supplemental Material (http://www. 
ehponline.org/members/2008/0800073/
suppl.pdf)]. The model includes 15 organs 
as well as arterial, venous, and portal blood 
compartments. The organs are connected 
via blood flows, and the circulation system 
is closed via the lung. We coupled the sub-
models on export to MoBi (version 2.0; Bayer 
Address correspondence to A.N. Edginton, School of 
Pharmacy, University of Waterloo, 200 University 
Ave.  W,  Waterloo,  ON,  Canada  N2L  3G1. 
Telephone: (519) 888-4567 ext. 21315. Fax: (519) 
888-7910. E-mail: aedginto@uwaterloo.ca
Supplemental Material is available online at http://
www.ehponline.org/members/2008/0800073/suppl.pdf
We thank M. Sevestre for assistance with the sen-
sitivity analysis. 
The authors declare they have no competing 
  financial interests.
Received 6 August 2008; accepted 14 November 
2008.
Predicting Plasma Concentrations of Bisphenol A in Children Younger Than 
2 Years of Age after Typical Feeding Schedules, using a Physiologically Based 
Toxicokinetic Model
Andrea N. Edginton1 and Len Ritter2
1School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada; 2Department of Environmental Biology, University of Guelph, 
Guelph, Ontario, Canada
ba c K g r O u n d: Concerns have recently been raised regarding the safety of potential human exposure 
to bisphenol A (BPA), an industrial chemical found in some polycarbonate plastics and epoxy resins. 
Of particular interest is the exposure of young children to BPA via food stored in BPA-containing 
packaging.
Objectives: In this study we assessed the age dependence of the toxicokinetics of BPA and its 
glucuronidated metabolite, BPA-Glu, using a coupled BPA–BPA-Glu physiologically based toxico-
kinetic (PBTK) model.
Me t h O d s : Using information gathered from toxicokinetic studies in adults, we built a PBTK 
model. We then scaled the model to children < 2 years of age based on the age dependence of physi-
ologic parameters relevant for absorption, distribution, metabolism, and excretion.
re s u l t s: We estimated the average steady-state BPA plasma concentration in newborns to be 
11 times greater than that in adults when given the same weight-normalized dose. Because of the 
rapid development of the glucuronidation process, this ratio dropped to 2 by 3 months of age. 
Simulation of typical feeding exposures, as estimated by regulatory authorities, showed a 5-fold 
greater steady-state BPA plasma concentration in 3- and 6-month-olds compared with adults, 
reflecting both a reduced capacity for BPA metabolism and a greater weight-normalized BPA expo-
sure. Because of uncertainty in defining the hepatic BPA intrinsic clearance in adults, these values 
represent preliminary estimates.
cO n c l u s i O n s: Simulations of the differential BPA dosimetry between adults and young children 
point to the need for more sensitive analytical methods for BPA to define, with greater certainty, the 
adult hepatic BPA intrinsic clearance, as well as a need for external exposure data in young children.
Key w O r d s : bisphenol A, ontogeny, physiologically based toxicokinetics. Environ Health 
Perspect 117:645–652 (2009).  doi:10.1289/ehp.0800073 available via http://dx.doi.org/ [Online 
14 November 2008]Edginton and Ritter
646  v o l u m e  117 | n u m b e r 4 | April 2009  •  Environmental Health Perspectives
Technology Services GmbH), a software pack-
age for the mechanistic and dynamic mod-
eling of biologic processes and drug action. 
We linked the two submodels such that the 
hepatic clearance of BPA was the only source 
function for the BPA-Glu submodel, where 
the process was defined in the liver.
PBTK Model Parameterization
BPA and BPA-Glu physicochemistry. Table 1 
presents physicochemical and physiologic 
parameters of BPA and BPA-Glu.
Anatomical and physiologic parameters. 
We previously published the body weight, 
height, blood flows, and organ volumes for 
children and adults, as used in the PK-Sim 
software (Edginton et al. 2006b). Table 2 
presents these parameter values as used in the 
pediatric and adult models for this study.
Absorption. The oral absorption model 
is that of Willmann et al. (2003b, 2004), 
and this model provided BPA input to the 
portal vein. We considered scaling the gas-
trointestinal parameters of gastrointestinal 
geometry, gastric emptying time, intestinal 
permeability, gastric and intestinal pH, small 
intestinal transit time, and intestinal surface 
area to children between 0 and 2 years of age. 
However, because of the high absorbed frac-
tion (fa = 1) of orally administered BPA, these 
various inputs did not make a life-stage dif-
ference. As a result, all simulations used an 
fa value of 1.
Distribution. We used the algorithms of 
Rodgers and Rowland (2006) and Rodgers 
et al. (2005a, 2005b) to estimate tissue:plasma 
partition coefficients. Required input data 
were the fraction unbound in plasma, lipo-
philicity, and acid/base properties. Table 1 
presents these input data for BPA and BPA-
Glu. We slightly modified the Rodgers and 
Rowland (2006) and Rodgers et al. (2005a, 
2005b) algorithm for children with respect 
to the interplay between neutral lipids and 
extracellular water. The volume fraction lipids 
in adipose tissue increases with age (Baker 
1969) due to an adipocyte generation and 
cell volume growth (Boulton et al. 1978; 
Soriguer Escofet et al. 1996; Spalding et al. 
2008). A relationship between the volume 
fraction lipids and interstitial space with age 
has been previously developed to adjust the 
adipose:plasma partition coefficient (Edginton 
et al. 2006b). We similarly altered the 
Rodgers and Rowland (2006) and Rodgers 
et al. (2005a, 2005b) algorithm through the 
interplay between the volume fraction neutral 
lipids and extracellular water for children. 
Permeability × surface area (PS) products 
define the rate of organ/tissue uptake and are 
estimated in PK-Sim. PS scaling to children 
used the following allometric function:
    
PStissue_child = PStissue_adult
Vtissue_child
Vtissue_adult
⎛
⎝
⎜
⎞
⎠
⎟
0.75
,
 
 [1]
where V is the volume of the tissue.
Elimination. BPA clearance (CLBPA_liver). 
We assumed that 100% of the elimination of 
BPA was attributable to metabolism to its 
glucuronidated metabolite, BPA-Glu. This is 
supported by Volkel et al. (2002), who deter-
mined that recovery of an isotope of BPA-Glu 
in plasma after human trials was equivalent to 
that of total BPA after addition of a glucuroni-
dase. The enzyme responsible for this has 
not been directly assessed in humans. In 
rats, the responsible rat-specific isozyme is 
UDP-glucuronosyltransferase (UGT) 2B1 
(UGT2B1) (Yokota et al. 1999). This rat-
  specific isozyme has a sequence and a substrate 
specificity similar to the human UGT2B7 
isozyme. Using full-length rat UGT2B1 as a 
probe in a human cDNA library, one of two 
full-length clones was found to be UGT2B7 
(Coffman et al. 1997), as characterized by 
Jin et al. (1993). Soars et al. (2003) demon-
strated that dog UGT2B31, rat UGT2B1, 
and human UGT2B7 display similar sub-
strate specificities, and that dog UGT2B31 
had sequence alignments that were 75% 
and 73% identical to human UGT2B7 and 
rat UGT2B1. Using morphine, a known 
Table 1. BPA and BPA-Glu compound properties.
Property  BPA  BPA-Glu
Lipophilicity  Log Kow = 3.4 (Staples et al. 1998)  –0.05a
Molecular weight (g/mol)  228; 244b   404; 418b
pKa  9.6, 10.2 (Staples et al. 1998)  Used same as for BPA
Water solubility (mg/L)  120–300 (Staples et al. 1998)  NA
Blood:plasma ratio  1.05c  0.83c
Plasma protein binding  Kd = 100 nmol/mL (Csanady et al. 2002)  fu = 95% (deduced from Volkel et al. 2002)
 f u = 3.5%
Intestinal permeability (Pint)  2.8 × 10–5; 2.6 × 10–5a  NA
Abbreviations: NA, not applicable. 
aOptimized value using experimental plasma concentration time data from Volkel et al. (2002). bRelevant for Volkel et al. 
(2002) simulations because they administered d16-BPA. The first printed value was used for all simulations in children. 
cEstimated in PK-Sim. Experimental BPA blood:serum ratio in rats is 1.1 (Shin et al. 2004).
Figure 1. Schematic of the PBTK model structure consisting of BPA and BPA-Glu submodels. Input of BPA 
was to the stomach, thus simulating oral administration. Input of BPA-Glu was the hepatic metabolism of 
BPA to BPA-Glu in the liver.
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UGT2B7 substrate, as a probe, Pritchard et al. 
(1994) showed morphine glucuronidation 
at the 3-position by rat UGT2B1 with high 
velocity, a result confirmed by Soars et al. 
(2003) with the addition of minute observed 
amounts the 6-O-glucuronide. Coffman et al. 
(1997) have shown conclusively that human 
UGT2B7 can catalyze morphine glucuroni-
dation at both the 3- and 6-positions, but 
the isozyme was approximately 10-fold more 
efficient at forming the 3-O-glucuronide. 
Another study examining the UGT respon-
sible for diclofenac glucuronidation in 
humans found that rat UGT2B1 and human 
UGT2B7 both catalyzed this reaction with 
similar affinities (King et al. 2001). Based 
on the evidence of UGT2B1 and UGT2B7 
sequence similarities and substrate overlaps, 
we considered UGT2B7 the enzyme respon-
sible for BPA glucuronidation and thus used 
the enzyme ontogeny of UGT2B7 to scale the 
intrinsic clearance of BPA to BPA-Glu from 
adults to children. UGT2B7 activity in term 
neonates is only 5% that of adults, increases 
to 30% by 3 months of age, and reaches adult 
levels by 1 year of age (Edginton et al. 2006a).
We described the method of scaling clear-
ance from adults to children (Edginton et al. 
2006a). In brief, for hepatically cleared com-
pounds, the plasma clearance (CLH; milliters 
per minute) from adults is converted to an 
intrinsic clearance (CLint; milliters per min-
ute) using the well-stirred model (Equation 2) 
and physiologic information of liver blood 
flow (QH; mL/min) and the fraction unbound 
in plasma (fu):
     
CLint = CLH
QH
QH − CLH
×
1
fu
.  [2]
Clearance is then normalized to liver 
weight (milliters per minute/grams liver) and 
multiplied by the percentage of activity rel-
evant to the age of the child to derive a liver 
weight–normalized intrinsic clearance for 
the child. Plasma clearances for children are 
derived by rearrangement of Equation 2 and 
by using the age-specific liver weight, blood 
flow, and estimated fu as derived using the 
method of McNamara and Alcorn (2002). 
This method adjusts the fu in adults to chil-
dren based on the age dependence of albumin 
concentrations in plasma (McNamara and 
Alcorn 2002).
BPA-Glu clearance (CLBPA-Glu_kidney). 
Urinary excretion is 100% responsible for 
BPA-Glu clearance in humans (Volkel et al. 
2002). We optimized plasma CLBPA-Glu_kidney 
during the development of the adult cou-
pled model and compared this with values 
derived from Volkel et al. (2002). We also 
compared the estimated time course of BPA 
urinary excretion with that from Volkel 
et al. (2002). Allometric relationships as 
described by Hayton (2000) and modified 
slightly by Edginton et al. (2006a) formed 
the basis for scaling the age dependence of 
CLBPA-Glu_kidney.
We used the following equation to cal-
culate the total BPA (BPA + BPA-Glu) aver-
age urinary concentration at steady state 
(CBPA_urine):
  CBPA_urine = MBPA × fe⁄Vurine,  [3]
where MBPA is the mass of BPA ingested 
per day, fe is the fraction excreted to urine, 
and Vurine is the volume of urine produced 
in 1 day. fe is 1 because 100% of the BPA 
dose is converted to BPA-Glu, and 100% of 
BPA-Glu is excreted to urine, results observed 
by Volkel et al. (2002). A linear interpola-
tion of Vurine, as taken from the International 
Commission on Radiological Protection 
(ICRP 2002), provided values for newborns 
and for 3-month-, 6-month-, 1-year-, 2-year-, 
and 30-year-olds of 300, 320, 350, 400, 425, 
and 1,600 (adult male) mL/day, respectively. 
Lakind and Naiman (2008) used this equa-
tion in a rearranged form to calculate the daily 
BPA exposure from urinary concentrations 
and daily urine volume.
Development of the Adult 
BPA–BPA‑Glu Coupled Model
We parameterized the BPA and BPA-Glu 
models in PK-Sim for an average 30-year-
old male of 73 kg and 176 cm (ICRP 2002). 
We used the experimental plasma concen-
tration time data of BPA-Glu after BPA 
administration from Volkel et al. (2002) to 
parameterize the unknown data of CLBPA_liver, 
BPA-Glu lipophilicity (used for calculation 
of tissue:plasma partition coefficients), and 
CLBPA-Glu_kidney. We simulated a BPA oral 
dose of 5 mg (Volkel et al. 2002). We set 
CLBPA_liver for this male at the lowest inte-
ger that maintained the BPA concentrations 
lower than the 10-nM limit of detection from 
the Volkel et al. (2002) study. We then cou-
pled the BPA and BPA-Glu submodels in 
MoBi to reflect the metabolism process. The 
change of intracellular concentration due to 
BPA metabolism to BPA-Glu (CLBPA_liver) 
is calculated as (CLBPA_liver × Ccell_liver_BPA × 
fu_BPA/Kliver_BPA)/Vcell_liver, where Ccell_liver_BPA 
is the concentration of BPA in the liver intra-
cellular space, fu_BPA is the unbound frac-
tion of BPA in plasma, Kliver_BPA is the 
liver:plasma partition coefficient, and Vcell_liver 
is the intracellular volume of the liver [see 
Supplemental Material for full differen-
tial equations (http://www.ehponline.org/
members/2008/0800073/suppl.pdf)].
The only unknown parameters at this 
point were the lipophilicity of BPA-Glu and 
CLBPA-Glu_kidney. We optimized these param-
eters using the plasma concentration–time 
data of BPA-Glu for all subjects studied by 
Volkel et al. (2002). The objective function 
was the           root mean squared error measured 
as the root of the squared difference between 
the predicted and observed plasma concen-
trations for both compounds. For optimiza-
tion, we used the Mobi-Toolbox for MatLab 
(Bayer Technology Services GmbH) and the 
MatLab [version 7 (R14); MathWorks Inc., 
Natick, MA, USA] fminsearch optimization 
routine without constraints. We used the 
optimized BPA-Glu lipophilicity in all simu-
lations for children as a means to predict par-
tition coefficients. We scaled the optimized 
Table 2. Parameter values of body weight, body height, and hematocrit as well as organ or tissue volumes 
(g) and organ blood flows (mL/min) as used in the adult and pediatric PBTK models.
  Age
Tissue  Newborn  3 months  6 months  1 year  1.5 years  2 years  Adulta
Adipose  906/30  1,758/55  2,596/67  3,666/60  3,999/75  4,245/90  14,868/325
Body height (cm)  51  58  65  76  82  88  176
Body weight (kg)  3.5  5.4  7.2  10.0  11.7  13.0  73.0
Bone  452/30  677/44  922/53  1,377/60  1,696/80  1,940/97  11,818/324
Brain  395/180  576/306  754/448  988/700  1,077/898  1,151/1,095  1,508/780
Gonads  1.1/0.3  1.3/0.4  1.5/0.5  1.8/0.6  2/0.8  2/1  40/3
Hematocrit  0.58  0.35  0.36  0.36  0.36  0.36  0.47
Heart  28/24  38/34  48/40  66/48  80/65  90/80  417/260
Kidneys  38/110  55/160  72/192  103/230  126/311  141/378  438/1,325
Large intestine  21/24  30/35  40/42  58/48  72/63  84/76  412/260
Liver  185/39  256/55  325/65  452/78  552/106  627/131  2,357/423
Lung  84/588  119/906  153/1,167  216/1,536  264/2,016  295/245  1,294/6,106
Muscle  968/31  1,311/45  1,628/55  2,215/72  2,767/95  3,287/116  32,338/1,106
Pancreas   9/6  13/9  19/11  28/12  35/16  39/20  190/65
Skin  216/30  281/42  334/49  417/60  483/79  529/95  3,761/325
Small intestine  36/60  52/86  68/103  99/120  125/160  148/194  724/650
Spleen  17/18  25/26  33/32  49/36  60/49  68/60  243/195
Stomach  8/6  12/9  16/10  23/12  29/16  35/19  168/65
Venous blood  38  48  55  68  85  101  691
Arterial blood  38  48  55  68  85  101  691
Portal blood  57  72  83  102  127  151  1,037
Double values are organ weight (g)/organ blood flow (mL/min).
aVolume represents “wet weight” where vascular volume is added to organ volume as given in ICRP (2002).Edginton and Ritter
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adult CLBPA-Glu_kidney to children as previ-
ously described. During the scaling procedure 
and simulations in children, we allowed no 
changes to the coupled model structure.
Scaling the Adult Coupled Model to 
Children
Once we set the adult model of BPA and 
BPA-Glu, we made changes to scale the model 
to children. We used the following age-specific 
parameters: weight, height, organ volumes, 
blood flows, volume fraction of fat in adipose 
tissue, tissue:plasma partition coefficients, PS, 
CLBPA_liver, CLBPA-Glu_kidney, and fu.
Simulations
First, we completed simulations after a BPA 
application of 1 µg/kg once per day to dem-
onstrate the expected differences in the aver-
age dose-normalized plasma concentrations 
at steady state of BPA and BPA-Glu in adults 
and young children (0–2 years of age). Second, 
we used published environmental exposure 
data (EFSA 2006) (Table 3) to estimate the 
average plasma concentration at steady state 
in children and adults under typical feeding 
scenarios. Because EFSA (2006) exposure sce-
narios did not include breast-fed newborns, 
we included this group by calculating exposure 
based on average daily breast milk intake and 
total BPA concentration in breast milk. The 
average daily breast milk intake is 13 g/kg on 
the first day of life, increases gradually 98 g/kg 
on day 3, and reaches a relatively constant level 
of 155 g/kg from day 5 (Casey et al. 1986). In 
the early days, using the highest concentration 
of free plus conjugated BPA from Ye et al. 
(2008), which is 1.62 µg/L, 95% of which was 
free BPA, the newborn (postnatal age = 5 days; 
3.5 kg) would receive 0.88 µg of BPA per day, 
assuming that all conjugated BPA is cleaved in 
the gastrointestinal tract. We also simulated 
this exposure scenario. We took average con-
centrations at steady state as the average con-
centration over one dosing interval after the 
system reached steady state. After simulations 
of a 1-µg/kg/day intravenous (iv) bolus at all 
ages, we calculated BPA bioavailability (F) as
     
F =
AUCpo × Doseiv
AUCiv × Dosepo
,  [4]
where AUC is the area under the simulated 
plasma concentration time curve for an iv or 
peroral (po) BPA dose.
Sensitivity Analysis
We used local sensitivity analysis here to pri-
oritize the impact of the input parameters on 
the outcome of interest: the average steady-
state plasma concentration (Cavg_ss). We used 
its simplest form where an input parameter 
value (Pin) is changed by 1% and the rela-
tive change in outcome is calculated when all 
other input parameters are fixed:
     
ΔCavg_ss
ΔPin
×
Pin
Cavg_ss
.  [5]
We performed all sensitivity analyses 
based on a BPA dose of 1 µg/kg/day for an 
adult. We used sensitivity analyses to assess 
the variation of both BPA and BPA-Glu 
organ/tissue volumes (18), organ blood flows 
(14), hematocrit (1), fu (1), organ:plasma par-
tition coefficients (15), red blood cell partition 
coefficient (1), red blood cell permeability 
(1), organ PS (15), organ-specific PSrbc (18), 
intrinsic hepatic clearance of BPA (1), and 
intrinsic kidney clearance of BPA-Glu (1) on 
Cavg_ss of both BPA and BPA-Glu.
Results
Adult BPA–BPA-Glu coupled model. The 
plasma CLBPA_liver required to keep the 
first data point (51 min) below the limit of 
detection of 10 nM (Volkel et al. 2002) was 
21 mL/min/kg. This corresponded to 88% 
of liver blood flow. The optimized plasma 
clearance (CLBPA-Glu_kidney) for the urinary 
excretion of BPA-Glu and the BPA-Glu lipo-
philicity were 1.82 mL/min/kg and –0.05, 
respectively. CLBPA-Glu_kidney was equal to that 
derived by Volkel et al. (2002). At 12 and 
24 hr, the estimated dose excreted to urine 
was 83% and 91%, compared with 91% 
and 94% as observed by Volkel et al. (2002), 
respectively. Table 4 presents the estimated 
tissue:plasma partition coefficients for BPA 
and BPA-Glu for adults and children. Table 5 
presents the PS products for adults. Figure 2 
presents the optimized plasma concentration 
time profiles for BPA and BPA-Glu in adults.
Simulations in children and adults. 
At all ages, 100% of the applied BPA dose 
was modeled as absorbed to the portal vein 
Table 3. Estimated BPA exposure scenarios for infants > 3 months of age taken from the EFSA (2006) report 
and breast-fed newborn exposure as calculated from Casey et al. (1986) and Ye et al. (2008).
Age  Food/beverages consumed  Exposure/day (µg/kg)   No. of feedings/day
Newborn  Breast-fed only  0.25  8
3 months  Breast-fed only  0.2  8
3 months  Formula fed with polycarbonate bottle  4.0a (11.0b)  8
6 months  Formula fed with polycarbonate bottle  8.3a (13.0b)  6
    and commercial foods/beverages
1.5 years  2 kg commercial foods/beverages  5.3  6
Adult  3 kg commercial foods/beverages  1.5  4
aBased on a conservative value for migration of BPA into infant formula (EFSA 2006). bBased on an upper value for migra-
tion of BPA into infant formula (EFSA 2006).
Table 4. The ratio of estimated plasma unbound fraction in children (fu,child) to the reported unbound frac-
tion in adults (fu,adult) and the estimated tissue:plasma partition coefficients for BPA and BPA-Glu.
Parameter  BPAa  BPA-Glua  Shin et al. (2004)b  Yoo et al. (2000)  Csanady et al. (2002)c
fu,child/fu,adult (age)         
  Term neonate  1.29  1.01     
  3 months  1.28  1.01     
  6 months  1.27  1.01     
  1 year  1.25  1.01     
  2 years  1.23  1.01     
Adipose (age)         
  Term neonate  3.8  0.59     
  3 months  5.6  0.43     
  6 months  5.7  0.42     
  1 year  5.8  0.41     
  2 years  5.9  0.40     
  30 years  8.3  0.18  0.7 ± 0.6    3.31 ± 0.17
Bone  1.7  0.42     
Brain  3.6  0.75  4.4 ± 0.6  0.75  1.06 ± 0.09
Gonads  0.79  0.83  3.4 ± 0.5  2.8 
Heart  1.6  0.57  3.4 ± 1.0  3.3 
Kidneys  1.8  0.68  4.4 ± 0.7  4.9  1.35 ± 0.17
Large intestine  3.8  0.75    4.1 
Small intestine   3.8  0.75  45.96 ± 3.2 
Stomach  3.8  0.75  4.6 ± 0.9  4.1 
Liver  1.9  0.65  5.7 ± 2.2  2.0  1.46 ± 0.38
Lung  2.4  0.58  5.5 ± 0.5  5.7 
Muscle  2.2  0.74  0.8 ± 0.1    1.35 ± 0.31
Pancreas   3.9  0.65     
Red blood cells  1.1  0.65     
Skin  5.7  0.69     
Spleen  1.0  0.55  2.8 ± 0.8  2.9 
aThe age-specific partition coefficient is the product of the ratio of unbound fractions and the partition coefficient. 
bEx vivo exposure (mean ± SD) of 4–5 g of cut-up human tissue to BPA over 6 hr in a flask; n = 3–4. cBPA exposure to rats 
via multiple intravenous infusions, with tissues taken at around 3.5 hr (n = 2 rats) and 4.5 hr (n = 2 rats) after dose initiation.Predicting bisphenol A plasma concentrations in children
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(fa = 1), although there was an increase in 
the efficiency of first-pass metabolism with 
increasing age. Bioavailability (F) in new-
borns and 3-month-, 6-month-, 1.5-year-
olds, and adults was 88%, 48%, 32%, 23%, 
and 18%. In all simulations, BPA and BPA-
Glu steady state was reached within the first 
48 hr. Figure 3 presents average plasma con-
centrations at steady state and urinary con-
centrations for children and adults after BPA 
administration of 1 µg/kg/day. Figure 4 pres-
ents the average plasma concentrations at 
steady state of BPA and BPA-Glu as well as 
the expected urinary concentrations after typi-
cal exposure scenarios in children and adults.
Sensitivity analysis. Values > 1 were of 
interest in that they identified input parame-
ters that had potential to greatly affect Cavg_ss. 
No varied parameter in the BPA model pro-
duced a value > 1, with respect to BPA aver-
age steady-state concentrations, although 
values to note (> 0.1) were fu (0.98), hema-
tocrit (0.16), and intrinsic hepatic clearance 
(0.89). No varied parameter in the BPA 
model, with respect to BPA-Glu average 
steady-state concentrations, produced a value 
greater than 1. No parameter in the BPA-
Glu model, with respect to BPA-Glu average 
steady-state concentrations, produced a value 
> 1, although a value to note was intrinsic 
renal clearance (0.80).
Discussion
Existing PBTK models of BPA and/or 
BPA-Glu were not appropriate for use in 
this scaling study. Teeguarden et al. (2005) 
described a partial PBTK model consisting 
of five compartments for BPA and a one-
  compartment model for BPA-Glu. Teeguarden 
et al. (2005) parameterized this rat model 
using in vivo data from rats after BPA expo-
sure with subsequent scaling to humans. The 
lumped compartments in the model did not 
provide an appropriate structure that could 
account for the relevant physiologic inputs 
that are required to reliably scale from adult 
humans to children. This necessitated the use 
of another model. Shin et al. (2004) adopted 
a more whole-body PBTK approach and used 
in vivo data from rats for parameterization. 
Their model focused on BPA, not BPA-Glu. 
Further, they measured tissue:plasma parti-
tion coefficients 3–4 hr after initial exposure, 
which for a lipophilic compound such as BPA 
would not be sufficient to reach steady state. 
The result was a partition coefficient in adipose 
tissue that was lower than all other organs as 
well as blood, a result in stark contrast to data 
from Csanady et al. (2002), who demonstrated 
in ex vivo experiments that the adipose:plasma 
partition coefficient was two to three times 
higher than all other tested tissues. Although 
in rat this value may not be particularly impor-
tant for describing the kinetics of a lipophilic 
compound, because only approximately 4% 
of body weight is adipose tissue, humans have 
approximately 15–30% of body weight as adi-
pose tissue, so this value is greatly influential. 
Table 4 presents experimental tissue:plasma 
partition coefficients from various experimental 
studies (Csanady et al. 2002; Shin et al. 2004; 
Yoo et al. 2000). The estimated partition coef-
ficients from the Rodgers and Rowland (2006) 
and Rodgers et al. (2005a, 2005b) algorithm 
were within range of the experimental values 
and deemed reasonable for use in this model. 
Based on the above limitations in existing BPA 
models, we used a whole-body PBTK model 
previously used for scaling drug pharmaco-
kinetics from adults to children (Edginton 
et al. 2006b). This model has been shown to 
be physiologically consistent in adults and in 
children down to newborns. Some examples of 
this consistency include the following: sum of 
blood flows = cardiac output; sum of splanch-
nic organs = portal vein flow; total body water, 
lipid, and protein is age dependent and con-
sistent with the literature; and addition of 
blood pool volumes and vascular volume for 
each organ = total blood content (Edginton 
et al. 2006b). With the integration of the 
Rodgers and Rowland (2006) and Rodgers 
et al. (2005a, 2005b) algorithm for partition 
coefficient estimation, and the gastrointestinal 
tract model of Willmann et al. (2003b, 2004), 
all relevant physiology could be accounted in 
order to scale BPA and BPA-Glu from adults 
to children.
Optimization of the BPA-Glu lipophilicity 
parameter as a means to estimate tissue:plasma 
partition coefficients from the Rodgers and 
Rowland (2006) and Rodgers et al. (2005a, 
2005b) algorithm resulted in a BPA-Glu distri-
bution volume that was equivalent to that from 
the Volkel et al. (2002) study (0.43 L/kg). 
BPA-Glu partition coefficients were, on aver-
age, 10 times lower than those of BPA. This 
is reasonable because glucuronidation and, in 
general, phase II metabolism aim at increas-
ing water solubility and thus, in the absence of 
specific binding, results in lower partition coef-
ficients than for the parent compound.
Young children are physiologically dif-
ferent from adults, and this could be consid-
ered in the PBTK model that we developed 
for BPA and BPA-Glu. The activity of many 
hepatic enzymes is lower at birth, and the 
activity increase with age occurs at an enzyme-
specific rate (Edginton et al. 2006a). In the 
case of BPA, we considered UGT2B7 the 
enzyme responsible for BPA hepatic clear-
ance, where newborns had only 5% of the 
enzymatic activity of the adult liver. This 
was also responsible for a relative lack of 
first-pass effect in newborns (F = 88%) and 
subsequently a bioavailability decrease with 
age. Taken with a distribution change over 
age (↑ fu, ↓ Kadipose), the dose-normalized 
BPA plasma concentrations at steady state 
were a maximum of 11 times higher than 
that in adults. As enzyme activity reached that 
of adults at 1 year of age, the dose-normal-
ized BPA plasma concentrations at this age 
were lower than in adults because of a higher 
weight-normalized plasma clearance. This 
Table 5. Permeability × surface area (PS) products (L/min) for BPA and BPA-Glu for adults.
  BPA  BPA-Glu
Parameter  PSorgan  PSrbc_organ  PSorgan  PSrbc_organ
Venous/arterial    1,675    0.018
Adipose  4,725  648  0.051  6.9 × 10–3
Bone  4,766  973  0.051  0.010
Brain  0.51  142  5.4 × 10–6  1.5 × 10–3
Gonads  82  5.7  8.9 × 10–4  5.7 × 10–5
Heart  3,123  142  0.033  1.5 × 10–3
Kidneys  14,427  244  1.2  2.6 × 10–3
Large intestine  5,145  24  0.83  2.6 × 10–3
Liver  25,389  971  0.27  0.010
Lung  59  1,819  6.3 × 10–4  0.019
Muscle  2,752  1,959  0.029  0.020
Pancreas   16,529  92  2.3  9.9 × 10–4
Portal vein blood    2,513    0.027
Skin  17  419  1.9 × 10–4  4.5 × 10–3
Small intestine  18,116  42  1.3  4.5 × 10–4
Spleen   60,468  195  2.8  2.1 × 10–3
Stomach  24,035  13  2.4  1.4 × 10–4
rbc, red blood cells.
Figure 2. Simulated BPA and BPA-Glu plasma con-
centration time profile for an adult male after oral 
administration of BPA. Observed data taken from 
Volkel et al. (2002).
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phenomenon has been documented previ-
ously (Edginton et al. 2006a). It is of inter-
est that this pediatric PBTK model has been 
previously used to scale the pharmacokinetics 
of the UGT2B7 substrate morphine to chil-
dren with acceptable accuracy (Edginton et al. 
2006b). Adult morphine plasma clearance, 
primarily due to hepatic UGT2B7 activity, 
is 20.5 mL/min/kg for adults (Edginton et al. 
2006a), a clearance similar to that defined 
for BPA UGT2B7 plasma clearance (21 mL/
min/kg). Thus, the scaling of BPA clearance 
follows closely with that of morphine. 
It is important here to note the limita-
tions of the model with respect to clearance 
scaling. We generated the BPA plasma clear-
ance in adults based on maintenance of the 
BPA plasma concentrations that were lower 
that the limit of detection in the Volkel et al. 
(2002) study. This value of 21 mL/min/kg 
represented the lower bound of clearance 
because we could still meet the criteria given a 
higher clearance up to a blood flow limitation 
at around 24 mL/min/kg, with little change 
in BPA-Glu concentrations (average BPA-Glu 
concentrations not sensitive to hepatic intrinsic 
clearance in the BPA model). For the purposes 
of clearance scaling, our approach to using 
the lower bound represented the “worst-case 
scenario” when scaling to children. Scaling 
clearance for a blood flow limited clearance 
compound is not possible because intrinsic 
clearance approaches infinity when blood flow 
equals blood clearance. In this case, the activ-
ity of the enzyme is unknown, and the clear-
ance in the child could reach 100% of hepatic 
blood flow despite a reduction in intrinsic 
enzyme activity. Thus, the method we used 
to generate an adult clearance was the most 
conservative with respect to pediatric clear-
ance scaling because it represented a worst-
case scenario. Further, when clearance scaling 
to young children, there exists uncertainty 
when using enzyme activity ontogeny data 
(Bjorkman 2006) because a period of high 
interindividual variability is present between 
the postnatal onset and expression increase of 
hepatic enzymes (Hines 2007). This has been 
demonstrated for glucuronidating enzymes 
(Strassburg et al. 2002) and is expected to 
be relevant to this discussion regarding BPA. 
Therefore, the clearance scaling method is 
built on average in vitro activity levels and is 
not conservative in predicting plasma concen-
trations in the most developmentally delayed 
pediatric liver.
We performed a sensitivity analysis to 
assess the relative importance of the input 
parameters in affecting the average steady-
state BPA concentrations. We performed only 
a local sensitivity analysis here, so any sig-
nificant parameter correlations would not be 
revealed using this method. We found that 
BPA and BPA-Glu concentrations were not 
hypersensitive to any one parameter in the 
model. Of interest to BPA concentrations 
were the fraction unbound in plasma (0.98) 
and the hepatic intrinsic clearance of BPA 
(0.89). For the BPA-Glu concentrations, the 
parameter renal intrinsic clearance of BPA-
Glu (0.80) was of interest. To be confident 
in our scaled model for children, ensuring the 
accuracy of these parameters for children is 
important. We scaled the fraction unbound 
in plasma from adults based on the method 
of McNamara and Alcorn (2002), a method 
demonstrated to be useful for a wide variety 
of drugs within a varied binding range. This 
scales the binding fraction based on the age-
dependent levels of the binding protein (albu-
min) in blood. In the absence of experimental 
data, this algorithm represents the best means 
of scaling the unbound fraction to children. 
The hepatic intrinsic clearance, as previously 
discussed, is not readily discernable from the 
experimental data currently available. For 
the purposes of clearance scaling, although 
UGT2B7 ontogeny has been widely exam-
ined (Alcorn and McNamara 2002; de Wildt 
et al. 1999; Edginton et al. 2006a), the actual 
adult intrinsic clearance is a difficult param-
eter to measure given the lack of sensitive 
analytical techniques for BPA and the border-
line blood flow limitation of clearance in the 
adult. Given the relative importance of this 
parameter on the outcome of this model, its 
uncertainty may denigrate the modeling effort 
to a screening level exercise as opposed to 
a definitive study and suggests the need to 
determine adult BPA clearance with certainty. 
We scaled the renal clearance of BPA-Glu 
based on the method of Hayton (2000), 
as modified for children < 2 days of age by 
Edginton et al. (2006a). This method rep-
resents the most widely used renal clearance 
scaling algorithm (Alcorn and McNamara 
2008), and we expect that it accurately pre-
dicted renal BPA-Glu clearance in children 
< 2 years of age. 
Volkel et al. (2005) measured plasma 
concentrations in 19 randomly chosen, unin-
tentionally exposed individuals. Plasma con-
centrations of total BPA (after glucuronidase 
treatment) in adults were always below the 
limit of detection of 0.5 µg/L (Volkel et al. 
2005). The average steady-state plasma con-
centration of total BPA in adults after a typi-
cal exposure of 1.5 µg/kg/day was 0.58 µg/L 
(Figure 4), which suggests that this estimated 
exposure value is higher than that of the 
population studied by Volkel et al. (2005). 
We took typical BPA exposures for adults 
and children from an EFSA review (2006), 
although other exposure scenarios have been 
documented (Lakind and Naiman 2008; NTP 
2008). Because only using passive diffusion 
processes explain the kinetics and because lin-
ear BPA and BPA-Glu clearance are assumed, 
plasma concentrations can be scaled directly 
with daily exposure dose. This is also the case 
with urinary concentrations. Using the expo-
sure scenarios of EFSA and assuming conser-
vative migration behavior of BPA from food 
containers (EFSA 2006), BPA average plasma 
concentrations at steady state in 3-month-
olds (4 µg/kg/day) and 6-month-olds (8.3 µg/
kg/day) were approximately five times greater 
than those in adults. Breast-fed newborns and 
3-month-olds, under typical exposure scenar-
ios, had concentrations 1.8-fold and 0.26-fold, 
respectively, that in adults (Figure 4).
Because of the relative ease of urine sam-
pling compared with blood sampling, the 
greatest body of exposure literature is based on 
Figure 3. Estimated BPA and BPA-Glu average steady-state plasma concen-
trations in children and adults after a 1-µg/kg/day oral administration of BPA. 
Total BPA = BPA + BPA-Glu urinary concentration.
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urinary concentrations of BPA after sampling 
of unintentionally exposed individuals. The 
literature contains little information on chil-
dren. Based on urinary BPA concentrations, 
there was a tendency toward higher calculated 
BPA intakes and urinary concentrations in 
children and adolescents 6–19 years of age 
(Lakind and Naiman 2008) compared with 
adults. We showed higher urinary concentra-
tions in young children than in adults (Figure 
4) under typical exposure scenarios, although 
our urinary concentrations were approximately 
25 times higher than those found in adults 
in both the Lakind and Naiman (2008) and 
Dekant and Volkel (2008) studies, leading 
to doubt as to how typical the EFSA expo-
sure scenarios really are. Although Dekant and 
Volkel (2008) suggested that there is an uncer-
tainty of approximately one order of magni-
tude when using single spot urine samples to 
estimate total daily intake by an individual, 
as was the case in the Lakind and Naiman 
(2008) and Dekant and Volkel (2008) stud-
ies, the EFSA (2006) exposure scenarios are 
apparently high-end estimates of BPA intake 
for adults and likely also for young children. 
Determining actual daily intakes in children 
< 6 years of age, as recommended by Lakind 
and Naiman (2008), is important because 
real exposures in this age group are unknown. 
Once urinary concentrations are known, back-
calculations can be made to estimate daily 
exposures, and then, using the PBTK model, 
circulating BPA plasma concentrations may 
be estimated. This can be of interest when 
assessing the risks associated with BPA expo-
sure in children. Urinary concentrations at 
steady state can be used to back-calculate to 
daily exposures (Lakind and Naiman 2008), 
although this does not indicate the internal 
BPA load. Input of the estimated daily expo-
sure into the PBTK model could be used to 
estimate the circulating BPA concentration 
and/or tissue concentrations of interest. In this 
second step, however, uncertainly exists such 
that there is interplay between plasma con-
centrations and enzyme activity (for BPA) or 
urinary clearance (for BPA-Glu) that cannot 
be directly known simply from a urine sample. 
Reducing this uncertainty would require direct 
validation of the PBTK model in young chil-
dren. This validation would come in the form 
of blood concentrations of BPA and BPA-
Glu in a number of young children. Once 
acceptance and/or modification of the model 
is completed, we can extrapolate among ages, 
doses, and disease states as well as estimate tis-
sue loads with greater confidence.
In summary, we developed a PBTK cou-
pled model system for BPA and its metabo-
lite, BPA-Glu, in adults and scaled to children 
based on age-dependent physiologic param-
eters. Because of low UGT2B7 activity, BPA 
plasma concentrations could be approximately 
11 times greater in newborns than in adults 
exposed to the same weight-normalized dose. 
An increase in age to 3 months lowers this 
ratio to 2, although exposure through food 
can be greater in this age group than in adults 
(EFSA 2006; NTP 2008). When consider-
ing different feeding scenarios, the highest 
and lowest BPA concentrations differed by a 
factor of 55. Thus, age-dependent differences 
may be substantial but cannot be absolutely 
quantified because of a need for both clearer 
understanding of the in situ hepatic intrin-
sic BPA clearance in the adult and urinary 
concentrations in children < 6 years of age 
to define daily BPA intake. As a worst-case 
scenario, these findings suggest that the typi-
cal intraspecies uncertainty/safety factor of 10 
commonly applied to a threshold dose (Pest 
Management Regulatory Agency 2007) is just 
sufficiently protective of very young children 
who have average or above average glucuroni-
dation capacity. EFSA derived a tolerable 
daily intake of 50 µg (BPA)/kg based on the 
application of a 100-fold uncertainly factor 
(10 for interspecies differences and 10 for 
interindividual differences) to a no observable 
adverse effect level of 5 mg/kg/day in rats. It is 
apparent from this modeling study that new-
borns with less than average glucuronidation 
capacity may not be adequately considered 
based on a factor of 10 to account for human 
variability in BPA toxicokinetics.
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